Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-3032b in Relapsed/Refractory Multiple Myeloma
NCT02579824Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of milademetan in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Aug 2016; status: terminated.
02
Drugs
milademetan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02579824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579824.